These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 33)

  • 21. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
    Medof ME; Gottlieb A; Kinoshita T; Hall S; Silber R; Nussenzweig V; Rosse WF
    J Clin Invest; 1987 Jul; 80(1):165-74. PubMed ID: 2439544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
    Medof ME; Kinoshita T; Silber R; Nussenzweig V
    Proc Natl Acad Sci U S A; 1985 May; 82(9):2980-4. PubMed ID: 2581259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis.
    Rosse WF; Hoffman S; Campbell M; Borowitz M; Moore JO; Parker CJ
    Br J Haematol; 1991 Sep; 79(1):99-107. PubMed ID: 1716964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. II. The role of complement components in the increased sensitivity of PNH red cells to immune lysis.
    Rosse WF; Dacie JV
    J Clin Invest; 1966 May; 45(5):749-57. PubMed ID: 4956901
    [No Abstract]   [Full Text] [Related]  

  • 25. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes. Studies on C9 binding and incorporation into high molecular weight complexes.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Exp Med; 1986 Oct; 164(4):981-97. PubMed ID: 3760783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody.
    Rosse WF; Dacie JV
    J Clin Invest; 1966 May; 45(5):736-48. PubMed ID: 5935361
    [No Abstract]   [Full Text] [Related]  

  • 27. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5430-4. PubMed ID: 6225118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced complement-mediated lysis of type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9 binding and polymerization.
    Hu VW; Nicholson-Weller A
    Proc Natl Acad Sci U S A; 1985 Aug; 82(16):5520-4. PubMed ID: 3860874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-lymphocytes escape membrane defect in paroxysmal nocturnal haemoglobinuria.
    Cooper MR; Currie MS; Rustagi PK; Logue GL
    Br J Haematol; 1983 Oct; 55(2):263-71. PubMed ID: 6604541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A platelet and granulocyte membrane defect in paroxysmal nocturnal hemoglobinuria: usefulness for the detection of platelet antibodies.
    Aster RH; Enright SE
    J Clin Invest; 1969 Jul; 48(7):1199-210. PubMed ID: 5798625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of cryptantigen Th on paroxysmal nocturnal hemoglobinuria erythrocytes in association with a hemolytic exacerbation.
    Nakakuma H; Hidaka M; Nagakura S; Nishimura Y; Iwamoto N; Horikawa K; Kawaguchi T; Kagimoto T; Takatsuki K
    J Clin Invest; 1995 Jul; 96(1):201-6. PubMed ID: 7542278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.
    Holguin MH; Wilcox LA; Bernshaw NJ; Rosse WF; Parker CJ
    J Clin Invest; 1989 Nov; 84(5):1387-94. PubMed ID: 2478585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of the enhanced susceptibility of paroxysmal nocturnal hemoglobinuria erythrocytes to complement-mediated hemolysis initiated by cobra venom factor.
    Parker CJ; Stone OL; Bernshaw NJ
    J Immunol; 1989 Jan; 142(1):208-16. PubMed ID: 2909615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complement-mediated granulocyte dysfunction in paroxysmal nocturnal hemoglobinuria.
    Craddock PR; Fehr J; Jacob HS
    Blood; 1976 Jun; 47(6):931-9. PubMed ID: 1276474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lysis of red blood cells in some haemolytic anaemias--the lytic effect of agkistrodon piscivorus venom in vitro.
    Brabec V; Kornalík F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1977; 104(3):428-35. PubMed ID: 72030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protease-modified erythrocytes: CD55 and CD59 deficient PNH-like cells.
    Yuan FF; Bryant JA; Fletcher A
    Immunol Cell Biol; 1995 Feb; 73(1):66-72. PubMed ID: 7539403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of the acetylcholinesterase activity of AET-treated (2-aminoethylisothiouronium bromide) normal red cells (PNH-like cells).
    Ferrone S; Zanella A; Sirchia G
    Acta Vitaminol Enzymol; 1970; 24(6):222-5. PubMed ID: 5537936
    [No Abstract]   [Full Text] [Related]  

  • 39. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
    Nicholson-Weller A; March JP; Rosenfeld SI; Austen KF
    Proc Natl Acad Sci U S A; 1983 Aug; 80(16):5066-70. PubMed ID: 6576376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
    Sica M; Rondelli T; Ricci P; De Angioletti M; Risitano AM; Notaro R
    J Hematol Oncol; 2017 Jun; 10(1):126. PubMed ID: 28629435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.